Published in J Hepatol on April 28, 2008
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59
Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol (2011) 1.28
Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 1.27
Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol (2013) 1.15
Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res (2010) 1.06
HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann Rheum Dis (2013) 0.97
Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci (2011) 0.94
Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med (2014) 0.92
Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Dig Dis Sci (2008) 0.89
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. Br J Cancer (2011) 0.88
Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J Hepatol (2008) 0.85
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs (2014) 0.84
Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. Oncotarget (2015) 0.82
mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment. Biomed Res Int (2014) 0.82
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget (2015) 0.77
Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol (2012) 0.77
Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res (2009) 0.76
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab. EJNMMI Res (2017) 0.75
Interferon-α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity. Exp Ther Med (2014) 0.75
Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report. Oncologist (2010) 0.75
Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma. World J Gastroenterol (2009) 0.75
Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet (2017) 0.75
Hypoxia as a target for drug combination therapy of liver cancer. Anticancer Drugs (2017) 0.75
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30
Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). Genome Res (2007) 4.99
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med (2012) 4.90
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Perforation of the gastrointestinal tract secondary to ingestion of foreign bodies. World J Surg (2006) 4.71
Expressed pseudogenes in the transcriptional landscape of human cancers. Cell (2012) 4.22
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res (2010) 4.06
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J (2005) 3.23
The journal impact factor: too much of an impact? Ann Acad Med Singapore (2006) 2.98
Phylogeographic reconstruction of a bacterial species with high levels of lateral gene transfer. BMC Biol (2009) 2.94
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res (2008) 2.87
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell (2011) 2.78
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem (2008) 2.72
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol (2009) 2.69
STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell (2012) 2.66
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res (2008) 2.56
CT in the preoperative diagnosis of fish bone perforation of the gastrointestinal tract. AJR Am J Roentgenol (2006) 2.54
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology (2013) 2.46
Predictive factors of malignancy in adults with intussusception. World J Surg (2006) 2.37
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut (2012) 2.36
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
Genomic patterns of pathogen evolution revealed by comparison of Burkholderia pseudomallei, the causative agent of melioidosis, to avirulent Burkholderia thailandensis. BMC Microbiol (2006) 2.35
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis (2008) 2.24
Mutations in sodium-borate cotransporter SLC4A11 cause recessive congenital hereditary endothelial dystrophy (CHED2). Nat Genet (2006) 2.20
A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathological features of 344 patients. World J Surg (2006) 2.15
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet (2013) 2.15
Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology (2014) 2.11
Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells (2006) 2.11
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med (2013) 2.07
Digital pathology: exploring its applications in diagnostic surgical pathology practice. Pathology (2010) 2.05
Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res (2011) 2.05
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther (2007) 2.01
An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies. J Thorac Oncol (2007) 1.98
Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet (2009) 1.96
Retroperitoneal schwannoma. Am J Surg (2006) 1.93
Exome sequencing: dual role as a discovery and diagnostic tool. Ann Neurol (2012) 1.89
Function of the SIRT1 protein deacetylase in cancer. Biotechnol J (2007) 1.88
Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol (2003) 1.88
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res (2011) 1.86
Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther (2006) 1.84
Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol (2011) 1.81
The airborne metagenome in an indoor urban environment. PLoS One (2008) 1.81
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab (2012) 1.80
Outcome after surgical treatment of suspected gastrointestinal stromal tumors involving the duodenum: is limited resection appropriate? J Surg Oncol (2008) 1.77
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn (2009) 1.76
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood (2003) 1.74
RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest (2009) 1.71
RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res (2005) 1.71
Genetic algorithms applied to multi-class prediction for the analysis of gene expression data. Bioinformatics (2003) 1.70
Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. Eur Urol (2012) 1.69
Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res (2013) 1.67
Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res (2011) 1.67
JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res (2012) 1.67
Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J Natl Cancer Inst (2014) 1.66
A genomic survey of positive selection in Burkholderia pseudomallei provides insights into the evolution of accidental virulence. PLoS Pathog (2010) 1.65
Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer (2008) 1.65
GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat. Free Radic Biol Med (2009) 1.63
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res (2011) 1.63
The effect of photodynamic therapy on tumor angiogenesis. Cell Mol Life Sci (2009) 1.62
A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther (2006) 1.61
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer (2004) 1.60
A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res (2003) 1.60